Skip to content
type1.science
Phase 3Not yet recruitingNCT06909006

Semaglutide phase 3 in T1D with obesity

What this study tests

Investigator-initiated phase 3 trial (sponsor Nordsjaellands Hospital, per registry) testing weekly semaglutide titrated to 2.4 mg versus placebo for weight, insulin-dose needs, glycemic outcomes, and hypoglycemia and DKA safety in adults with established T1D and obesity.

Editorial review: .

Registry checked: 2026-09-17. Registry’s own update: 2025-08-08.

Source dates appear in the references where available; this record has no dated citation metadata.

Trial status, labels and access can change between reviews. How we review the evidence · How to read the evidence

Full sources ↓Full discussion ↓Report an issue →

Evidence at a glance

Who can enter the study?
Adults (18 and older, per registry) with T1D for more than 3 years and BMI at least 30 kg/m², or BMI at least 27 with at least one listed comorbidity, per the registry. The registry’s primary outcome is body weight over 68 weeks of treatment plus a 6-week follow-up (74-week timeframe), not restoration of insulin-producing cells. Registered eligibility ↗Enrollment criteria describe who may enter. They do not establish who was analyzed or the denominator for a reported result.
Reported benefit and results
No results posted yet.Read the result sources and their limitations →
Important harms
Read the reported results, safety discussion and original sources. A separate harms summary is not available; this does not establish safety.
Research access and approval
Study regions: European Union. A trial listing does not establish product approval or current recruitment at a particular site. Check the study’s current entry requirements.
What remains uncertain?
Read the full discussion and original sources for study limitations. Planned endpoints and completion dates are not results.

Research status alone does not establish approval, clinical benefit or local availability.

Primary endpoints

  • Body weight

The full picture

This record has no longer discussion. Use the study criteria, reported results and original sources on this page to assess what is known and what remains unresolved.

Sources

  1. [1]